scholarly journals Somatic mutations in arachidonic acid metabolism pathway genes enhance oral cancer post-treatment disease-free survival

2014 ◽  
Vol 5 (1) ◽  
Author(s):  
Nidhan K. Biswas ◽  
Subrata Das ◽  
Arindam Maitra ◽  
Rajiv Sarin ◽  
Partha P. Majumder
Keyword(s):  
Arachidonic Acid ◽  
Oral Cancer ◽  
Somatic Mutations ◽  
Acid Metabolism ◽  
Disease Free Survival ◽  
Arachidonic Acid Metabolism ◽  
Post Treatment ◽  
Free Survival ◽  
Metabolism Pathway ◽  
Disease Free

PCNA and anti-apoptotic Mcl-1 proteins predict disease-free survival in oral cancer patients treated with definitive radiotherapy

Oral Oncology ◽  
2010 ◽  
Vol 46 (9) ◽  
pp. 688-693 ◽  
Author(s):  
Sanchita Mallick ◽  
Jaiprakash Agarwal ◽  
Sadhana Kannan ◽  
Sagar Pawar ◽  
Shubhada Kane ◽  
...  
Keyword(s):  
Oral Cancer ◽  
Cancer Patients ◽  
Disease Free Survival ◽  
Free Survival ◽  
Definitive Radiotherapy ◽  
Oral Cancer Patients ◽  
Disease Free

Curietherapy of Oral Cancer

1982 ◽  
Vol 68 (2) ◽  
pp. 119-125 ◽  
Author(s):  
Fabio Volterrani ◽  
Fausto Chiesa ◽  
Roberto Molinari
Keyword(s):  
Oral Cancer ◽  
Hard Palate ◽  
Combined Treatment ◽  
Disease Free Survival ◽  
Free Survival ◽  
Floor Of Mouth ◽  
Disease Free ◽  
Mobile Tongue ◽  
Nodal Relapse

This work concerns 406 oral carcinomas treated with curietherapy (interstitial applications and surface molds) from January 1959 to December 1970. There were 65 (16.0%) carcinomas of the mucosal surface of cheeks, 15 of the retromolar areas, alveolus and gingiva, and hard palate (3.7%), 211 of the mobile tongue (51.9%), and 115 of the floor of mouth (28.4%). There were 132 (32.5%) T1 cases, 245 (60.3%) T2 and 29 (7.2%) T3. In 376 cases with adequate follow-up (92.6%) there were 93 (24.7%) local relapses: 83 isolated and 10 associated with a lymph nodal relapse; 49.5% of the local relapses were peripheral with respect to the treated volume (46/93). The incidence of local relapses only slightly differed for initially T1 and T2 cases (respectively 21.8% and 22.7%), whereas it was more than twice as much for initially T3 cases (53.6%). The overall incidence of radionecrotic complications was 22.0% (83/376 cases with adequate follow-up). Altogether the disease-free survival was 41.1% and 31.4% at 5 and 10 years, respectively. We think that local control of practically all treatable oral carcinomas can be obtained with a combined treatment.

scholarly journals INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO

2020 ◽  
Vol 19 (5) ◽  
pp. 61-67
Author(s):  
V. P. Shubin ◽  
Yu. A. Shelygin ◽  
S. I. Achkasov ◽  
O. I. Sushkov ◽  
A. A. Ponomarenko ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Peritoneal Carcinomatosis ◽  
Cancer Patients ◽  
Somatic Mutations ◽  
Disease Free Survival ◽  
Free Survival ◽  
The Status ◽  
Colorectal Cancer Patients ◽  
Disease Free

Purpose: to evaluate the effect of somatic mutations of the KRAS, NRAS, BRAF genes and the status of microsatellite instability on the overall and disease-free survival of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.Material and Methods. From 2012 to 2018, the study included 45 patients who underwent surgery for synchronous peritoneal carcinomatosis with colorectal cancer. In all patients, mutations of the KRAS, NRAS, BRAF genes and MSI status of the tumor and peritoneum metastases were determined using Sanger sequencing, fragment analysis and digital droplet polymerase chain reaction. The effect of mutations on patient survival was evaluated.Results. The prevalence of somatic mutations was 69 % of patients. The discordance between the tumor and peritoneum metastases was 9 %. All tumors and peritoneum metastases were microsatellite stable. KRAS, NRAS, BRAF mutations did not affect the overall and disease-free survival (p=0.87 and p=0.85, respectively).Conclusion. Somatic mutations in the KRAS, NRAS, or BRAF genes are not a prognostic factor affecting the overall and relapse-free survival of colorectal cancer patients with peritoneal carcinomatosis. The molecular status of primary tumor may differ from the status of peritoneal metastasis. It should be taken into account when prescribing targeted drugs. 

scholarly journals The Arachidonic Acid Metabolism Mechanism Based on UPLC-MS/MS Metabolomics in Recurrent Spontaneous Abortion Rats

2021 ◽  
Vol 12 ◽  
Author(s):  
Meihe Li ◽  
Yang Haixia ◽  
Minchao Kang ◽  
Peng An ◽  
Xili Wu ◽  
...  
Keyword(s):  
Arachidonic Acid ◽  
Spontaneous Abortion ◽  
Acid Metabolism ◽  
Ultra Performance Liquid Chromatography ◽  
Arachidonic Acid Metabolism ◽  
Recurrent Spontaneous Abortion ◽  
Metabolism Pathway ◽  
Liquid Chromatography Tandem Mass ◽  
Novel Biomarkers ◽  
Cox 1

Recurrent spontaneous abortion (RSA) remains a critical and challenging problem in reproduction. To discover novel biomarkers for RSA, ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) metabolomics approach was applied to detect RSA serum metabolic profiles and explore its possible pathogenesis and mechanism. The abortion rat model was established, and a metabolomics analysis was performed to evaluate the differentially expressed metabolites between the control and model groups. Immunohistochemistry (IHC), qRT-PCR, and Western blot further examined the expression of Arachidonic acid metabolism-related genes in uterus tissues. To identify arachidonic acid metabolism-related changes in RSA, ELISA’s potential mechanisms were further confirmed in serum. Ninety-one metabolites were significantly different between the two groups, as indicated by a VIP ≥1, fold change ≥1. The metabolic pathways involving arachidonic acid metabolism pathway (P = 0.00044) are related to RSA. Verification by experimental showed that compared with the control rats, the expression of the COX-1, COX-2, PTGFR, and TBXA2R genes associated with the arachidonic acid metabolism pathway has significantly increased the uterus and serum of RSA rats (P < 0.05). Regulation of the arachidonic acid metabolism pathway might serve as a promising therapeutic strategy for relieving RSA women’s symptoms.

Circulating tumor DNA analysis to detect minimal residual disease and predict recurrence in patients with resectable pancreatic cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16799-e16799
Author(s):  
Liu Yang ◽  
Jiahong Jiang ◽  
Song Ye ◽  
Yaping Xu ◽  
Dongsheng Huang
Keyword(s):  
Minimal Residual Disease ◽  
Somatic Mutations ◽  
Residual Disease ◽  
Disease Free Survival ◽  
Circulating Tumor Dna ◽  
Plasma Samples ◽  
Free Survival ◽  
Disease Free ◽  
Tumor Dna ◽  
Minimal Residual

e16799 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer death, partly due to the high recurrence rates for patients with resectable PDAC. Current postoperative surveillance methods including monitoring of clinical symptoms, tumor markers and CT imaging, lack sensitivity and specificity to identify minimal residual disease (MRD). Methods: We investigated whether the detection of circulating tumor DNA (ctDNA) could identify MRD and predict relapse in postoperative patients with PDAC. In this study, we performed panel-captured sequencing to detect somatic mutations. Matched tissue samples were obtained to verify mutation. Results: A total of 27 patients and 65 plasma samples were included. Among the somatic mutations, KRAS and TP53 were the most recurrent genes in both tissue and plasma samples. The detectable rate of ctDNA increased with the stage of PDAC. The maximal variant allele fraction (VAF) of ctDNA had a positive correlation with tumor largest diameter (p = 0.0101). Patients with ctDNA-positive status postoperatively had a markedly reduced disease-free survival (DFS) compared to those with ctDNA-negative status (HR, 5.20; p = 0.019). Positive vascular invasion significantly influenced disease-free survival (DFS) (p = 0.036), and positive postoperative ctDNA status was an independent prognostic factor for DFS (HR = 3.60; 95% CI, 1.15-11.28; p = 0.028). Conclusions: Postoperative ctDNA detection provides strong evidence of MRD and identifies patients with a high risk of relapse. ctDNA detection is a promising approach for personalized patient management during postoperative follow-up.

Sign in / Sign up

Export Citation Format

Share Document